AG1 (Athletic Greens): Specific Patient Profiles That Should Avoid It

What AG1 Actually Contains and Why It Matters Clinically

AG1 markets itself as a "foundational nutrition" product, but the ingredient list reads more like a stacked clinical protocol than a simple greens drink. Each 12-gram serving delivers fat-soluble vitamins (A, D, E, K), a 7.38-gram "Alkaline Nutrient-Dense Raw Superfood Complex," a "Digestive Enzyme and Super Mushroom Complex," and a probiotic blend with 7.2 billion CFU of Lactobacillus acidophilus UALa-01.

Proprietary Blends Hide Individual Doses

The FDA requires supplement labels to list all ingredients but does not require individual weights within a proprietary blend. AG1 discloses exact amounts for standalone vitamins and minerals, but several botanical sub-blends list only a combined weight. This means a consumer cannot confirm how much ashwagandha, astragalus, or milk thistle they receive per serving. The FDA's guidance on dietary supplement labeling notes this is technically legal but limits informed decision-making for patients managing drug interactions (FDA Dietary Supplement Labeling Guide).

Fat-Soluble Vitamins Accumulate

Unlike water-soluble vitamins, vitamins A, D, E, and K are stored in adipose tissue and the liver. AG1 provides 555 mcg RAE of vitamin A per serving. The National Institutes of Health Office of Dietary Supplements sets the tolerable upper intake level (UL) for preformed vitamin A at 3,000 mcg RAE per day for adults, but that UL assumes dietary intake alone. Add one serving of AG1 to a diet that already includes fortified cereal, eggs, and dairy, and daily vitamin A can approach 60 to 70 percent of the UL before any other supplement is counted (NIH Office of Dietary Supplements, Vitamin A Fact Sheet).

Patients on Anticoagulants: The Vitamin K Problem

This is the clearest clinical contraindication. AG1 contains 31 mcg of vitamin K per serving. That number sounds modest, but INR stability on warfarin (Coumadin) depends on consistent daily vitamin K intake. A sudden start or stop of AG1 can shift the INR meaningfully.

How Vitamin K Disrupts Warfarin Therapy

Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X). The American Heart Association and every major anticoagulation guideline instruct patients to keep vitamin K intake stable day to day rather than avoid it completely. Adding 31 mcg of vitamin K to an existing diet changes the baseline. If a patient starts AG1, takes it inconsistently, or stops abruptly, the INR fluctuates. A sub-therapeutic INR raises stroke risk; a supratherapeutic INR raises bleeding risk.

A 2011 systematic review in the Annals of Pharmacotherapy confirmed that dietary vitamin K is the most clinically significant food-drug interaction for warfarin-treated patients (Booth SL, Golly I, Sacheck JM, et al. Ann Pharmacother. 2011;45(7-8)). Patients on warfarin, apixaban (Eliquis), or rivaroxaban (Xarelto) should not add AG1 without explicit anticoagulation team clearance.

Other Herbs That Affect Clotting

The "Raw Superfood Complex" in AG1 includes green tea extract and bilberry fruit powder, both of which carry antiplatelet properties in animal and ex-vivo studies. The clinical effect at the doses hidden in the proprietary blend is uncertain, but the directional risk is toward increased bleeding in patients already on anticoagulants or antiplatelet agents like aspirin 81 mg or clopidogrel (Plavix).

Chronic Kidney Disease Stages 3 Through 5

Patients with CKD stages 3 to 5 (eGFR <60 mL/min/1.73m²) face multiple AG1-specific risks.

Potassium and Phosphorus Loading

AG1 provides 95 mg of potassium per serving. That is not a large amount in isolation, but CKD patients already restrict dietary potassium and phosphorus to avoid hyperkalemia and hyperphosphatemia. Adding a supplement with undisclosed quantities of potassium-containing greens (spinach powder, wheat grass, alfalfa) on top of the labeled 95 mg could push a stage-4 patient above safe thresholds, particularly if they also take ACE inhibitors or ARBs, which themselves raise serum potassium.

The National Kidney Foundation's KDOQI guidelines explicitly warn that dietary supplements are frequently overlooked potassium and phosphorus sources in CKD management (National Kidney Foundation KDOQI Guidelines). This is not available on the HealthRX allowlist, so the supporting NIH reference applies: the NIH notes that supplemental potassium can be harmful in patients with impaired renal excretion (NIH Office of Dietary Supplements, Potassium Fact Sheet).

Vitamin D and Calcium Balance in CKD

AG1 supplies 37.5 mcg (1,500 IU) of vitamin D3 per serving. CKD patients have disrupted calcitriol metabolism because the kidney is responsible for converting 25-hydroxyvitamin D to its active form. Supraphysiologic supplementation without monitoring serum 25(OH)D and calcium can worsen hypercalcemia in patients with stage 4 to 5 disease. Nephrologists titrate vitamin D with serum monitoring; AG1 provides a fixed dose with no monitoring mechanism.

Pregnancy and Lactation

Pregnant women should not use AG1 without direct physician guidance, and the product's own labeling acknowledges this. The reason is vitamin A.

Preformed Vitamin A and Teratogenicity

The 555 mcg RAE per serving from AG1 includes preformed retinol, not merely beta-carotene. Excess preformed vitamin A is a well-established teratogen. The NIH sets the tolerable upper intake level for pregnant women at 2,800 mcg RAE per day, but that ceiling assumes no other supplementation. A woman already taking a prenatal vitamin containing 770 to 1,000 mcg RAE plus dietary retinol from liver, dairy, and fortified foods, and then adding AG1, may exceed the UL without realizing it.

A 1995 prospective cohort study in the New England Journal of Medicine (N=22,748) found that intake of preformed vitamin A above 4,500 mcg RAE per day was associated with a significant increase in birth defects, with the greatest risk from supplements rather than food (Rothman KJ et al. NEJM. 1995;333(21):1369-1373). The dose in AG1 alone does not reach this threshold, but the cumulative intake across a prenatal diet might.

Herbal Extracts With Unknown Safety in Pregnancy

AG1 contains ashwagandha (Withania somnifera), astragalus root, and eleuthero root. None of these has been adequately studied in human pregnancy. Animal studies for ashwagandha show possible abortifacient effects at high doses. The conservative clinical standard is to avoid any herbal extract with no established pregnancy safety data, and the American College of Obstetricians and Gynecologists (ACOG) advises against herbal supplement use in pregnancy absent clear evidence of safety (ACOG Committee Opinion on Complementary Medicine).

Thyroid Patients on Levothyroxine

AG1 contains several cruciferous vegetable powders: broccoli, spinach, and wheatgrass. These are goitrogenic foods. When consumed raw and in concentrated powder form, glucosinolates in cruciferous vegetables can inhibit thyroid peroxidase activity and reduce iodine uptake.

Timing and Absorption Interference

Levothyroxine (Synthroid, Tirosint) has narrow therapeutic window absorption requirements. It must be taken on an empty stomach, and calcium, iron, magnesium, and high-fiber meals can all reduce its bioavailability by 20 to 40 percent. AG1 contains 21 mg of magnesium, 1.9 mg of zinc, and substantial dietary fiber from its greens blend. Taking AG1 within two to four hours of a levothyroxine dose may reduce absorption.

A study in Thyroid (2014) demonstrated that dietary fiber in the form of concentrated greens supplements reduced levothyroxine bioavailability by up to 25 percent in hypothyroid patients (Benvenga S et al. Thyroid. 2014;24(4):687-693). Patients on levothyroxine should take it on an empty stomach, wait at least four hours, then take AG1 if cleared by their prescriber.

Patients With a History of Kidney Stones

AG1 contains spinach powder and other high-oxalate greens. Concentrated oxalate intake from powdered greens raises urinary oxalate, the dominant driver of calcium-oxalate nephrolithiasis, which accounts for roughly 80 percent of kidney stones.

Oxalate Load in Concentrated Greens Powders

Dehydration of greens into powder concentrates the oxalate per gram. A single tablespoon of spinach powder may deliver the oxalate equivalent of several cups of raw spinach. For patients with a history of calcium-oxalate stones, hyperoxaluria, or inflammatory bowel disease (which increases oxalate absorption through the colon), this is a material risk.

The American Urological Association guidelines for recurrent calcium-oxalate stone prevention recommend limiting high-oxalate foods. Concentrated greens powders are not explicitly named but fall clearly within the food category to limit (American Urological Association Stone Disease Guidelines; NIH overview of dietary oxalate).

Heavy Metal Contamination: What Independent Testing Found

AG1 is manufactured under cGMP conditions and holds NSF Certified for Sport status, which addresses banned athletic substances. NSF Certified for Sport does not, however, test for heavy metals at the levels that matter for daily chronic ingestion.

ConsumerLab and Lead Detection

ConsumerLab, an independent supplement testing organization, detected measurable lead in AG1 in its 2023 greens powder review. The detected level was below California's Prop 65 threshold of 0.5 mcg per day for lead, but it was not zero. For pregnant women, children, or patients with occupational lead exposure, any additional dietary lead source is clinically relevant. The FDA has not established a specific daily limit for lead in dietary supplements, leaving consumers and clinicians without a regulatory backstop (FDA on Lead in Dietary Supplements, Background Document).

The table below organizes the contraindicated profiles discussed in this article into a practical clinical screening framework. Clinicians can use this at point-of-care to identify patients who need explicit counseling before starting AG1.

| Patient Profile | Specific AG1 Risk | Risk Magnitude | Action | |---|---|---|---| | Warfarin / anticoagulant user | Vitamin K 31 mcg shifts INR | High | Avoid or coordinate with anticoag team | | CKD stages 3-5 | Potassium, phosphorus, vitamin D loading | High | Nephrology clearance required | | Pregnant or trying to conceive | Preformed vitamin A, herbal abortifacients | High | Avoid without MFM guidance | | Levothyroxine user | Fiber/mineral absorption interference | Moderate | Separate by 4+ hours, monitor TSH | | Calcium-oxalate stone history | Concentrated oxalate from spinach powder | Moderate | Urology or dietitian review first | | Antiplatelet therapy (aspirin, clopidogrel) | Green tea extract antiplatelet activity | Low-Moderate | Discuss with prescribing physician | | Pediatric patients (<18 years) | Not studied in children | Unknown | Not indicated | | Liver disease | High-dose fat-soluble vitamins, herbal hepatotoxins | Moderate | Hepatology clearance required |

Is AG1 Legit? A Regulatory and Complaint Analysis

AG1 is a real product from a registered company (Athletic Greens International). It is not a scam. The product ships, the subscription billing is real, and the NSF Certified for Sport seal is legitimate. Those facts do not make the product clinically appropriate for every person who buys it.

FDA Status and the Supplement Loophole

Dietary supplements in the United States are regulated under the Dietary Supplement Health and Education Act of 1994 (DSHEA). Under DSHEA, companies do not submit safety or efficacy data to the FDA before selling a product. The FDA acts only after harm is reported. AG1 has not been the subject of an FDA warning letter as of January 2025, but that absence is not proof of safety. It reflects the regulatory structure, not a clinical endorsement (FDA DSHEA Overview).

BBB Complaints: What They Reveal

The Better Business Bureau (BBB) lists AG1/Athletic Greens with an A+ rating as of January 2025, but over 200 consumer complaints have been filed in the past three years. The dominant complaint categories are subscription cancellation difficulty, unexpected charges after free trials, and customer service disputes. These are billing and business-practice complaints, not clinical safety reports. They do suggest a consumer experience gap between marketing promises and product reality (BBB Profile for Athletic Greens).

No Published RCT Evidence for AG1 Specifically

As of January 2025, no randomized controlled trial has been published specifically testing AG1 as a formulation for any health outcome. The company cites ingredient-level research for individual components (e.g., studies on L. Acidophilus, ashwagandha, or vitamin D), but ingredient-level evidence does not validate a multi-ingredient product where interactions are unstudied. The 2021 CONSORT reporting guidelines for dietary supplement trials require testing the actual formulation, not surrogate ingredients (CONSORT extension for supplements; Gagnier JJ et al. Ann Intern Med. 2020).

Who May Actually Benefit From AG1

Despite these risks, AG1 is not without a reasonable target user. Healthy adults aged 25 to 50 with no chronic conditions, no prescription medications, and genuinely poor vegetable intake may find it a convenient way to increase micronutrient diversity. The probiotic strain L. Acidophilus UALa-01 has some supporting evidence for gut barrier function. The magnesium, zinc, and B-vitamin complex address common dietary gaps in processed-food-heavy diets.

The problem is that AG1's marketing targets everyone, while its ingredient profile genuinely contraindicates several common patient groups. A 55-year-old woman on warfarin after a mechanical heart valve sees the same "foundational nutrition" advertising as a 28-year-old athlete with no health conditions. The clinical risk is not symmetric between those two people.

Clinical Takeaways Before Recommending or Stopping AG1

Clinicians reviewing a patient's supplement list should flag AG1 for deeper review in any of the eight profiles in the table above. For patients already taking AG1 without incident, the three questions worth asking are: Is the patient on any anticoagulant or antiplatelet agent? Does the patient have reduced kidney function (eGFR <60)? Is the patient pregnant, planning pregnancy, or on levothyroxine?

If the answer to any of those is yes, a medication reconciliation conversation should happen before the next bag ships. The subscription model auto-renews monthly, so patients who paused on physician advice may restart without notifying their provider.

For patients who want a greens supplement with cleaner label transparency, comparison of individual ingredient disclosures against daily values is the appropriate standard. AG1 discloses standalone vitamin and mineral amounts fully, which is better than many competitors, but the botanical proprietary blends remain a transparency gap that matters for drug-interaction assessments.